Journal article

Cannabidiol for at risk for psychosis youth: A randomized controlled trial

G Paul Amminger, Ashleigh Lin, Melissa Kerr, Amber Weller, Jessica Spark, Charlotte Pugh, Sally O'Callaghan, Maximus Berger, Scott R Clark, James G Scott, Andrea Baker, Iain McGregor, David Cotter, Zoltan Sarnyai, Andrew Thompson, Alison R Yung, Brian O'Donoghue, Eoin Killackey, Cathy Mihalopoulos, Hok Pan Yuen Show all



BACKGROUND: No biological treatment has been firmly established for the at-risk stage of psychotic disorder. In this study we aim to test if subthreshold psychotic symptoms can be effectively treated with cannabidiol (CBD), a non-psychoactive compound of the plant Cannabis sativa. The question has taken on increased importance in the wake of evidence questioning both the need and efficacy of specific pharmacological interventions in the ultra-high risk (UHR) for psychosis group. METHODS: Three-arm randomized controlled trial of 405 patients (135 per arm) aged 12-25 years who meet UHR for psychosis criteria. The study includes a 6-week lead-in phase during which 10% of UHR individuals are exp..

View full abstract